Mounjaro becomes the first GIP/GLP-1 receptor agonist cleared to lower MACE risk, based on the SURPASS-CVOT head-to-head trial.
|Articles|September 23, 2022
- September 2022
- Volume 88
- Issue 09
Pet Peeves: September 2022
Brought to you by The Sassy Pharmacist
Advertisement
Fourth Time’s the Charm
The pharmacist triple-counts the medication, and the patient recounts it in the drive-through.
Ignored Advice
Patients who ask for a recommendation and then buy something else.
Wrong Number
Patients who call the pharmacy asking about front-of-store items.
What’s Bothering You?
Bossy patients, abandoned prescriptions, drive-through demands? We want to know! Send your pet peeves to cmollison@pharmacytimes.com. We’ll share them here and online.
Articles in this issue
about 4 years ago
Adlarity From Coriumabout 4 years ago
Generic Product News: September 2022about 4 years ago
Pharmacists Are Empowered Yet Againabout 4 years ago
Rx Products News: September 2022about 4 years ago
OTC Cases: September 2022about 4 years ago
ABM Offers Opportunity for Professional Growthabout 4 years ago
Court Addresses Liability in Dispensing Controlled Substancesabout 4 years ago
Mitigate Risk for Errors Involving Paxlovidabout 4 years ago
OTC Products: September 2022Advertisement
Related to this article
Community pharmacies are access points, safe places, and sources of stability when everything else feels uncertain.
Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
Walgreens adds virtual coverage navigation, Medicare GLP-1 Bridge support, and pharmacist follow-up calls as GLP-1 discontinuation remains high.
Joshua J. Neumiller, PharmD, CDCES, of the American Diabetes Association discusses pharmacists’ role in diabetes and CKD care from ASN Kidney Week 2026
A helpful guide for pharmacists if teas, supplements, or cultural foods are part of a patient's regular routine.
Jai Radhakrishnan, MD, discusses why IgG4-related kidney disease is often missed and what MITIGATE subgroup data presented at ASN Kidney Week 2026 show
Real-world data from ASN Kidney Week show GLP-1 RA users with CKD and obesity had lower rates of kidney failure, death, and heart failure exacerbation.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Cystatin C and the Future of Kidney Function Assessment
2
FDA Approves Talazoparib With Enzalutamide for HRR-Mutated Metastatic Prostate Cancer
3
Medicare GLP-1 Bridge Runs Outside Part D and Pharmacy Teams Need a Different Workflow
4
GLP-1 RAs, Finerenone, and CKD: Key Data From Kidney Week 2026
5